BioCapital Europe 2018, organised by LSP (Life Sciences Partners) is delighted to announce its 16th consecutive event, taking place on Tuesday 6 February 2018 in Amsterdam, The Netherlands.
BioCapital Europe of [...]
Breda, the Netherlands / Ghent, Belgium, June 20, 2017 - argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment [...]
Glepaglutide meets primary endpoint in Phase 2 trial in patients with short bowel syndrome
Glepaglutide* is a novel long-acting GLP-2 analogue
Reduction in fecal wet weight output of 30% and 23% i [...]
Breda, the Netherlands / Ghent, Belgium, June 14, 2017 - argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment [...]
Munich/Amsterdam – 13 June 2017 – LSP proudly announces that its portfolio company Probiodrug AG released encouraging results from its clinical trial in early Alzheimer’s disease patients. Treatment with Pro [...]
Human challenge study to assess safety, tolerability and efficacy of inhaled LASAG
Topline results expected end of 2017
Gemuenden, Germany, 31 May, 2017. Ventaleon GmbH, a biotechnology company focu [...]
Dasiglucagon is a potential first-in-class glucagon analogue for pump use in the management of type 1 diabetes
Data from this first Phase 2a trials indicate that dasiglucagon increases blood sugar levels a [...]
Amsterdam, The Netherlands – 19 May 2017 – It is with great pleasure that LSP – the specialist European healthcare investment firm – announces that its portfolio company argenx (Euronext Brussels: ARGX) was su [...]
Regulated information - inside information
Breda, the Netherlands / Ghent, Belgium, May 19, 2017 - argenx (Euronext & Nasdaq: ARGX) announced today that the underwriters of its initial public offering in th [...]
Results to be presented at the 2017 American Society of Clinical Oncology Annual Meeting
Phase 2 clinical trial to be initiated in second half of 2017 exploring two metastatic breast cancer populations: HER2- [...]
BioCapital Europe 2018, organised by LSP (Life Sciences Partners) is delighted to announce its 16th consecutive event, taking place on Tuesday 6 February 2018 in Amsterdam, The Netherlands.
BioCapital Europe of [...]
Breda, the Netherlands / Ghent, Belgium, June 20, 2017 - argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment [...]
Glepaglutide meets primary endpoint in Phase 2 trial in patients with short bowel syndrome
Glepaglutide* is a novel long-acting GLP-2 analogue
Reduction in fecal wet weight output of 30% and 23% i [...]
Breda, the Netherlands / Ghent, Belgium, June 14, 2017 - argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment [...]
Munich/Amsterdam – 13 June 2017 – LSP proudly announces that its portfolio company Probiodrug AG released encouraging results from its clinical trial in early Alzheimer’s disease patients. Treatment with Pro [...]
Human challenge study to assess safety, tolerability and efficacy of inhaled LASAG
Topline results expected end of 2017
Gemuenden, Germany, 31 May, 2017. Ventaleon GmbH, a biotechnology company focu [...]
Dasiglucagon is a potential first-in-class glucagon analogue for pump use in the management of type 1 diabetes
Data from this first Phase 2a trials indicate that dasiglucagon increases blood sugar levels a [...]
Amsterdam, The Netherlands – 19 May 2017 – It is with great pleasure that LSP – the specialist European healthcare investment firm – announces that its portfolio company argenx (Euronext Brussels: ARGX) was su [...]
Regulated information - inside information
Breda, the Netherlands / Ghent, Belgium, May 19, 2017 - argenx (Euronext & Nasdaq: ARGX) announced today that the underwriters of its initial public offering in th [...]
Results to be presented at the 2017 American Society of Clinical Oncology Annual Meeting
Phase 2 clinical trial to be initiated in second half of 2017 exploring two metastatic breast cancer populations: HER2- [...]
Follow us
